上海国瓴律师事务所 关于 江苏爱朋医疗科技股份有限公司 2023 年年度股东大会见证的 法律意见 上海国瓴律師事務所 SHANGHAIGUOLINGLAWFIRM 上海市闵行区秀文路 898 号西子国际中心 2 号楼 3 楼/徐汇区衡山路 598 号 电话：021-33883626 传真：021-34127367 网址：www.guolinglaw.com 2023 年年度股东大会见证的法律意见 上海国瓴律师事务所 关于 江苏爱朋医疗科技股份有限公司 2023 年年度股东大会见证的 法律意见 国瓴 2024009-2 号 致：江苏爱朋医疗科技股份有限公司 上海国瓴律师事务所（以下简称"本所"）受江苏爱朋医疗科技股份有限公 司（以下简称"公司"）委托，指派朱琴律师和曹一坤律师（以下合称"本所律 师"）出席公司 2023 年年度股东大会（以下简称"本次股东大会"），对本次 股东大会召开的合法性进行见证并出具本法律意见。 本所律师依据本法律意见出具日前已经发生或存在的事实和《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）、《上市公司股东大会规则（2022 年 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2024-024 江苏爱朋医疗科技股份有限公司 关于举行2023年度暨2024年第一季度网上业绩说明会的公告 为了便于投资者更全面地了解公司2023年度及2024年第一季度经营情况，公司定 于2024年5月21日（星期二）15:00-16:30 举行2023年度暨2024年第一季度网上业绩说明 会，本次业绩说明会将通过深圳证券交易所提供的"互动易"平台举行，投资者可登 陆"互动易" 网站（http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次业绩说 明会。 出席本次业绩说明会的人员有：公司董事长王凝宇先生、副总经理兼财务总监袁 栋麒先生、副总经理兼董事会秘书缪飞先生、独立董事侯利阳先生（如遇特殊情况， 参会人员可能进行调整）。 为充分尊重投资者，提升公司与投资者的交流效率和针对性，现就公司本次业绩 说明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可提前登 录深圳证券交易所互动易平台（http://irm.cninfo.com.cn）"云访谈"栏目，进入问题 征集专题页面进行提问。公司将在本次业绩说明会上，在信息披露 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥87,752,962, a decrease of 6.71% compared to ¥94,068,177 in the same period last year[5] - Net profit attributable to shareholders increased by 11.63% to ¥1,356,953.49 from ¥1,215,574.66 year-on-year[5] - The net profit after deducting non-recurring gains and losses surged by 76.41% to ¥1,720,177.95 compared to ¥975,082.81 in the previous year[5] - Net profit for Q1 2024 was CNY 1,127,308.15, a decrease of 9.8% from CNY 1,250,235.16 in Q1 2023[24] - Total operating revenue for Q1 2024 was CNY 87,752,962, a decrease of 6.0% compared to CNY 94,068,177.53 in Q1 2023[23] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥64,053,023.05, slightly worse than -¥60,865,461.63 in the same period last year, reflecting a decline of 5.24%[5] - The company's cash and cash equivalents decreased significantly by 76.13% to ¥47,944,359.60 due to investments in financial products[10] - The cash flow from financing activities showed a net inflow of ¥8,339,252.52, compared to a net outflow of ¥1,463,619.19 in the previous year[27] - The total cash and cash equivalents at the end of the period were ¥47,944,359.60, a decrease from ¥200,896,344.58 at the beginning of the period[27] - The cash and cash equivalents net increase was -¥152,951,984.98, compared to -¥205,250,243.54 in the same period last year[27] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥843,679,848.99, down 1.85% from ¥859,572,978.63 at the end of the previous year[5] - The total liabilities decreased to CNY 145,266,713.67 from CNY 162,377,151.47, reflecting a reduction of 10.5%[24] - The total current liabilities decreased to CNY 112,087,318.16 from CNY 129,873,385.02, a reduction of about 13.7%[20] - The total non-current assets amounted to CNY 413,540,432.67, slightly down from CNY 417,269,663.85[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,868[12] - The company reported a total of 45,053,063 shares under lock-up agreements, with a planned release date of August 6, 2025[16] - The company plans to increase its shareholding by at least CNY 5.4 million within six months from February 6, 2024, using self-raised funds[17] Operational Metrics - The company's cash received from sales of goods and services was CNY 69,016,477.25, down 13.8% from CNY 80,064,517.56 in Q1 2023[25] - Research and development expenses were CNY 7,677,023.64, down 20.7% from CNY 9,687,121.04 in Q1 2023[24] - Sales expenses decreased to CNY 24,765,360.77, a reduction of 21.0% from CNY 31,384,618.87 in the previous year[24] - Accounts receivable increased to CNY 162,468,844.13 from CNY 148,402,423.90, reflecting a growth of approximately 9.5%[19] - The company's inventory rose to CNY 59,059,390.73 from CNY 55,688,087.49, representing an increase of about 4.9%[19] - Short-term borrowings increased to CNY 49,237,875.14 from CNY 39,237,875.14, showing a rise of approximately 25.5%[20] Other Income and Expenses - Other income dropped by 82.84% to ¥1,263,464.93, primarily due to the absence of tax refunds[10] - Total operating costs decreased to CNY 86,636,436.82, down 12.5% from CNY 99,122,242.30 in the previous year[23] - The company distributed dividends and profits amounting to ¥332,166.81, slightly up from ¥322,328.19 year-over-year[27] - The cash outflow from financing activities totaled ¥1,750,747.48, a significant decrease from ¥11,363,619.19 in the previous year[27] Regulatory and Compliance - The company has not undergone an audit for the first quarter report[28] - Jiangsu Aipeng's subsidiary, Sichuan Jinjiazheng Medical Equipment Co., Ltd., received a medical device registration certificate for a third-class anesthesia depth monitor on February 5, 2024[17]

Financial Performance - The company's operating revenue for 2023 reached ¥422,170,460.93, representing a 30.38% increase compared to ¥323,808,133.90 in 2022[20]. - The net profit attributable to shareholders was ¥8,277,352.58, a significant turnaround from a loss of ¥76,377,405.54 in the previous year, marking a 110.89% improvement[20]. - The net profit after deducting non-recurring gains and losses was ¥4,835,442.71, compared to a loss of ¥82,281,748.42 in 2022, reflecting a 105.91% increase[20]. - The basic earnings per share improved to ¥0.0657 from a loss of ¥0.6059 in 2022, indicating a 110.89% increase[20]. - The total assets at the end of 2023 were ¥859,572,978.63, a decrease of 1.28% from ¥870,213,234.55 in 2022[20]. - The net assets attributable to shareholders increased by 1.50% to ¥696,203,485.91 from ¥685,580,361.21 in 2022[20]. - The company reported a net cash flow from operating activities of -¥23,335,844.92, an improvement of 5.12% from -¥24,593,930.44 in the previous year[20]. - The weighted average return on net assets was 1.20%, recovering from -10.43% in 2022[20]. - The company achieved total operating revenue of CNY 422.17 million, representing a year-on-year growth of 30.38%[61]. - The net profit attributable to shareholders of the listed company was CNY 8.28 million, an increase of 110.89% compared to the same period last year[61]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 4.84 million, up 105.91% year-on-year[61]. Market and Product Development - The company is focused on expanding its market presence and enhancing its product offerings through research and development initiatives[12]. - The company is focused on developing new products, including various infusion and anesthesia monitoring devices, to enhance its market position[20]. - The company is implementing strategies for market expansion and technological innovation to drive future growth[20]. - The company has established several private equity investment funds, indicating a strategy for financial diversification and investment in growth opportunities[12]. - The company is actively developing nasal cavity and upper airway management solutions, with products for various nasal diseases and sleep monitoring[55]. - The company is expanding its chronic pain management product line, including heat needle therapy devices, low-frequency therapy devices, and shock wave therapy devices[52]. - The company is exploring new consumer products in the fast recovery and medical beauty sectors, with a focus on perioperative management and recovery[59]. - The company is enhancing its innovation capabilities by incubating medical devices and optimizing resource allocation for industry development[59]. - The company is focusing on developing a closed-loop anesthesia system, which is expected to enhance its technological barriers in the market[113]. - The company is focusing on integrating advanced monitoring systems to support clinical data management and improve patient monitoring capabilities[116]. Strategic Initiatives and Investments - The company has established a clear strategy for capital allocation, including reinvestment into its core business areas and potential acquisitions to drive growth[12]. - The company has made significant advancements in pain assessment algorithms, utilizing machine learning and deep learning techniques[113]. - The company has established partnerships with multiple universities, achieving breakthroughs in pain management and anesthesia technology[74]. - The company has invested in Changzhou Ruishen'an Medical Equipment Co., which specializes in brain-machine interface technology and has developed products for epilepsy and pain treatment[53]. - The company has established a national-level postdoctoral research station and a provincial graduate work station to support talent development and technological innovation[93]. - The company plans to invest a total of CNY 26,293 million in various projects, with CNY 4,434.49 million allocated to the industrial base upgrade and CNY 18,078.98 million to the R&D center construction[148]. - The company has decided to terminate the marketing network construction project and reallocate the funds to the industrial base upgrade and R&D center projects to optimize financial structure and reduce risks[148]. - The company is focusing on creating greater value for shareholders by improving the efficiency of fund usage and financial structure[148]. Regulatory Compliance and Governance - The company is committed to complying with the disclosure requirements for medical device businesses as per the Shenzhen Stock Exchange guidelines[4]. - The company emphasizes the importance of risk awareness regarding future plans and development strategies, urging investors to understand the differences between plans, forecasts, and commitments[4]. - The report outlines the company's governance structure and commitment to environmental and social responsibilities, reflecting its corporate values[5]. - The company maintains transparency in information disclosure, ensuring that all investors have equal access to timely and accurate information[182]. - The company emphasizes the importance of investor relations management, appointing the board secretary as the responsible person for managing investor communications[183]. - The company has established independent financial and accounting systems, ensuring no interference from controlling shareholders[185]. - The company has a dedicated talent development department to manage human resources independently from its controlling shareholders[185]. Market Trends and Opportunities - The market for pain management devices is projected to grow at a compound annual growth rate (CAGR) of 13.8%, reaching a market size of 14.55 billion by 2026[32]. - The demand for "comfort healthcare" is increasing, driven by societal development and rising living standards, indicating a growing market opportunity for the company[31]. - The number of surgical procedures in China reached 82.72 million in 2022, with a CAGR of about 10%, highlighting a significant demand for postoperative pain management solutions[34]. - The company has identified a growing need for nasal care devices due to the rising incidence of upper respiratory infections, with 110.01 million ENT visits recorded in 2021[35]. - The global prevalence of sleep disorders is approximately 27%, with over 300 million individuals in China affected by sleep issues[36]. - The Chinese government has included sleep health in the "Healthy China Action (2019-2030)" initiative, indicating a growing market opportunity in sleep healthcare[36]. - The domestic medical device procurement policy has favored local manufacturers, leading to a significant increase in their winning bids[38]. Research and Development - The company reported a research and development investment of ¥36,549,133.77 in 2023, accounting for 8.66% of its operating revenue, a decrease from 10.79% in 2022[114]. - The number of R&D personnel decreased by 17.92% from 106 in 2022 to 87 in 2023, with a notable drop in the number of personnel holding master's degrees, down by 31.82%[114]. - The company has established a comprehensive quality control system covering all stages from R&D to after-sales, ensuring high product quality and compliance with ISO9001 and ISO13485 standards[95]. - The company is committed to ongoing research and development to enhance its product offerings and maintain a competitive edge in the medical technology market[116]. Corporate Social Responsibility - The company actively participates in public welfare while balancing the interests of shareholders, employees, and society[184]. - The company has been recognized as a "National Intellectual Property Advantage Enterprise" and a "National Employment and Social Security Advanced Private Enterprise" in 2023[44]. - The company has established a strong brand and channel advantage in the nasal care market, with its nasal care products leading in sales on platforms like Tmall and JD.com[91].

目 录 | 一、审计报告……………………………………………………… 第 1—5 | 页 | | --- | --- | | 二、财务报表……………………………………………………… 第 6—13 | 页 | | （一）合并资产负债表…………………………………………… 第 | 6 页 | | （二）母公司资产负债表………………………………………… 第 | 7 页 | | （三）合并利润表………………………………………………… 第 | 8 页 | | （四）母公司利润表……………………………………………… 第 | 9 页 | | （五）合并现金流量表……………………………………………第 | 10 页 | | （六）母公司现金流量表…………………………………………第 | 11 页 | | （七）合并所有者权益变动表……………………………………第 | 12 页 | | （八）母公司所有者权益变动表…………………………………第 13 | 页 | | | | 审 计 报 告 天健审〔2024〕3834 号 江苏爱朋医疗科技股份有限公司全体股东： 一、审计意见 我们审计了江苏爱朋医疗科技股份有限公司（以下简称爱朋医疗）财务报 ...

第一章 总 则 第一条 为规范江苏爱朋医疗科技股份有限公司（以下简称"公司"）监事 会的议事方式和决策程序，促使监事和监事会有效地履行职责，根据《中华人民共 和国公司法》（以下简称"《公司法》"）《上市公司治理准则》《深圳证券交易 所创业板股票上市规则》等有关法律、法规、规范性文件和《江苏爱朋医疗科技股 份有限公司章程》（以下简称"《公司章程》"）之规定制定本规则。 江苏爱朋医疗科技股份有限公司 监事会议事规则 第二条 监事会是公司的监督机构，向全体股东负责，以财务监督为核心， 根据《公司法》及其他有关法律、法规、规范性文件和《公司章程》的规定，对公 司财务以及公司董事、总经理和其他高级管理人员履行职责的合法、合规性进行监 督，维护公司及股东的合法权益。 监事会共 3 人，由股东监事与职工代表监事组成。其中职工代表监事由职工代表 大会或者其他形式民主选举产生。监事会设监事会主席 1 人，监事会主席由全体监 事过半数选举产生。 监事应当具有相应的专业知识或者工作经验，具备有效履职能力。公司董事、高 级管理人员不得兼任监事。董事、高级管理人员在任期间其配偶和直系亲属不得担 任公司监事。 第三条 监事会主席负责处理 ...

江苏爱朋医疗科技股份有限公司 2023年度财务决算报告 公司2023年度财务报表已经天健会计师事务所（特殊普通合伙）审计，并 于 2024年4月24日出具了天健审〔2024〕3834号标准无保留意见的审计报告。结果 如下：2023年全年实现营业总收入为42,217.05万元，同比增长30.38%；归属于上市 公司股东的净利润为827.74万元，同比增长110.89%。 一、 主要财务数据和指标 | 单位：万元 | | --- | | 项目 | 2023年度 | 2022年度 | 变动比率 | | --- | --- | --- | --- | | 营业总收入 | 42,217.05 | 32,380.81 | 30.38% | | 营业利润 | 1,396.65 | -8,832.37 | 115.81% | | 综合毛利率 | 65.55% | 49.43% | 16.12% | | 利润总额 | 1,380.88 | -9,070.92 | 115.22% | | 归属于上市公司股东的净利润 | 827.74 | -7,598.13 | 110.89% | | 扣非后的归属于母公司股东的净利润 | 483 ...

江苏爱朋医疗科技股份有限公司 第五条 公司董事会下设审计委员会、提名委员会、薪酬和考核委员会、 战略委员会四个专门委员会。审计委员会、薪酬与考核委员会、提名委员会 中独立董事应当过半数并担任召集人。其中审计委员会成员应当为不在公司 担任高级管理人员的董事，审计委员会的召集人应为会计专业人士。 第一条 为了促进江苏爱朋医疗科技股份有限公司（以下简称"公司"） 规范运作，维护公司整体利益，保障全体股东特别是中小股东的合法权益不 受损害，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司独立董事管理办法》（以下简称"《独立董事管理办法》"）《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关法律、行政法规、规范性文件和《江 苏爱朋医疗科技股份有限公司章程》（以下简称"《公司章程》"）之规定 制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及其 主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其 进行独立客观判断的关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单 位或者 ...

江苏爱朋医疗科技股份有限公司 2023 年度董事会工作报告 2023 年，江苏爱朋医疗科技股份有限公司（以下简称"公司"）董事会严格 遵守《公司法》《证券法》《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等法律法规的有关规定，忠实履行《公司章程》赋予的各 项职责，认真执行股东大会的各项决议，积极推进董事会各项决议实施。全体董事 恪尽职守、勤勉尽责，为董事会科学决策和规范运作做了富有成效的工作，有效地 保障了公司和全体股东的合法权益。2023 年度董事会工作报告如下： 一、 2023 年度公司总体经营情况 2023，公司实现营业总收入422,170,460.93元，较上年同期增长30.38%；归属 于上市公司股东的净利润8,277,352.58元，较上年同期增长110.89%。归属于上市公 司股东的扣除非经常性损益的净利润4,835,442.71元，较上年同期增长105.91%。 2023 年末，公司总资产达到 859,572,978.63 元，较期初同比减少 1.28%，归属 于上市公司股东的净资产合计 696,203,485.91 元，较期初同比增长 1.50%。 参阅公司 2 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2024-020 江苏爱朋医疗科技股份有限公司 关于修订《公司章程》的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 - 1 - | | 子产品销售；互联网销售（除销售需要许可 | 子产品销售；互联网销售（除销售需要许可 | | --- | --- | --- | | | 的商品）；物联网应用服务；技术服务、技 | 的商品）；物联网应用服务；技术服务、技 | | | 术开发、技术咨询、技术交流、技术转让、 | 术开发、技术咨询、技术交流、技术转让、 | | | 技术推广；信息咨询服务（不含许可类信息 | 技术推广；信息咨询服务（不含许可类信息 | | | 咨询服务）。（除依法须经批准的项目外， | 咨询服务）；化工产品销售（不含许可类化 | | | 凭营业执照依法自主开展经营活动） | 工产品）；专用化学产品销售（不含危险化 | | | | 学品）；工程和技术研究和试验发展；新型 | | | | 有机活性材料销售；化妆品批发；化妆品零 | | | | 售；智能无人飞行器销售；货物进出口；技 | | | ...